Recently, Kidney selleck kinase inhibitor Disease: Improving Global Outcomes (KDIGO) reported the definition, classification and prognosis of chronic kidney disease based on both estimated GFR and urinary Entinostat molecular weight levels of albumin excretion [20]. In this sense, there are diabetic patients with decreases in GFR and normoalbuminuria. Is diabetic nephropathy observed in such patients? In fact, the

percentage of diabetic patients with normoalbuminuria and low estimated GFR is believed to be relatively high. Importantly, Yokoyama et al. [21] described that the proportion of subjects with low estimated GFR (<60 ml/min/1.73 m2) and normoalbuminuria was 11.4% of the type 2 diabetic patients examined (262/2298). In this manuscript, 63.4% of the 262 patients studied had neither diabetic retinopathy nor neuropathy. On the other hand, these patients were older and included a higher proportion of women and GSK1904529A cost patients with hypertension, hyperlipidemia and cardiovascular disease, as well as fewer smokers compared with those with normoalbuminuria and preserved GFR. In contrast, the proportion of type 2 diabetic patients with preserved GFR but albuminuria or overt proteinuria was 27% (755/2791). Most importantly, the lack

of histologically proven diabetic nephropathy should be discussed. In type 1 diabetes patients with normoalbuminuria and low GFR, renal biopsy specimens revealed more advanced diabetic glomerular lesions. It is worth noting that a reduced GFR PLEK2 was found much more often among female patients, particularly if retinopathy and/or hypertension were also present [22]. Deep insight into the prevalence and prognoses of these patients with proven pathological characteristics and grading is required to understand the pathophysiology of diabetic nephropathy in greater depth, together with future perspectives. Clinical impacts of albuminuria

and GFR on the prognoses of diabetic patients Obviously, diabetic patients who had both albuminuria/overt proteinuria and low GFR were at risk of adverse outcomes, including cardiovascular events, cardiovascular death, and renal events, as reported by the Action in Diabetes and Vascular Disease: Preterax and DiamicroN MR Controlled Evaluation (ADVANCE) study [23] (Fig. 1). Do normoalbuminuric renally insufficient diabetic patients have a poor prognosis? Rigalleau et al. [24] reported that the risks of renal progression and death in these patients with type 1 or type 2 diabetes are lower. Concomitantly, in type 2 diabetic patients, the Casale Monferrato study revealed that macroalbuminuira was the main predictor of mortality, independently of both estimated GFR and cardiovascular risk factors, whereas the estimated GFR provided no further information on all-cause mortality and cardiovascular mortality in normoalbuminuric patients [25].